Kyntra Bio to Report First Quarter 2026 Financial Results
Kyntra Bio, a biopharmaceutical company focused on oncology and rare diseases, will report its first quarter 2026 financial results on May 11, 2026, followed by a conference call with investors. The company is advancing multiple drug candidates including Roxadustat, approved in several countries for anemia related to chronic kidney disease, and FG-…